Quick Answer
Sonoma Pharmaceuticals, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $18.63 million for the year ending 2021.
- Sonoma Pharmaceuticals, Inc. showed an increase of +3.9% in Revenue From Contract With Customer Excluding Assessed Tax from 2020 to 2021.
- This data is from Sonoma Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 14, 2021.
- XBRL data for this metric is available from 2019 to 2021 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $4.39 million | Q3 2019: $4.73 million | Q4 2019: $4.40 million | Q2 2020: $5.77 million | Q3 2020: $5.77 million | Q4 2020: $4.94 million | Q2 2021: $3.68 million | Q3 2021: $3.74 million | Q4 2021: $2.90 million.
- Over the full 3 years of available data (2019 to 2021), Sonoma Pharmaceuticals, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 1.8%.
- Historical annual values: Fiscal year 2021: $18.63 million | Fiscal year 2020: $17.93 million | Fiscal year 2019: $18.97 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: